USP Ticagrelor CAS 274693-27-5 Powder Fast Shipping Best Price

Ticagrelor More Info

Ticagrelor is an oral antiplatelet medication that plays a vital role in the management of cardiovascular diseases, particularly in preventing thrombotic events in patients with acute coronary syndrome (ACS) and those undergoing percutaneous coronary interventions (PCI). It belongs to the class of drugs known as adenosine diphosphate (ADP) receptor inhibitors, and it offers a unique mechanism of action and benefits compared to other antiplatelet agents.

Mechanism of Action

Ticagrelor works primarily by inhibiting the P2Y12 receptor, an ADP receptor found on the surface of platelets. When ADP binds to this receptor, it stimulates platelet activation and aggregation, which is a crucial step in the formation of blood clots. By reversibly binding to the P2Y12 receptor, ticagrelor prevents ADP from exerting its platelet-stimulating effects. This leads to a reduction in platelet activation and aggregation, thereby lowering the risk of thrombus formation.

Unlike some other ADP receptor inhibitors, ticagrelor is not a prodrug; it exerts its effects directly without requiring metabolic conversion in the liver. This characteristic enables ticagrelor to achieve a more rapid onset of action and allows for more consistent and predictable platelet inhibition.

Indications

Ticagrelor is primarily indicated for:

1. Acute Coronary Syndrome (ACS) : This includes both unstable angina and non-ST-elevation myocardial infarction (NSTEMI) as well as ST-elevation myocardial infarction (STEMI), where immediate and effective antiplatelet therapy is critical.
2. Percutaneous Coronary Intervention (PCI) : Ticagrelor is used in conjunction with aspirin in patients undergoing PCI to reduce the incidence of stent thrombosis and other thrombotic events.
3. Secondary Prevention of Cardiovascular Events : Ticagrelor is also employed in patients who have a history of myocardial infarction or other cardiovascular events to minimize the risk of future events.

Dosage and Administration

Typically, ticagrelor is administered orally, and the initial dosage may vary based on the specific indication and patient profile. The usual starting dose is 180 mg, followed by a maintenance dose of 90 mg twice daily. It is important for patients to take ticagrelor consistently as prescribed, with or without food, to maintain steady drug levels in the bloodstream.

Efficacy and Benefits

Clinical studies have demonstrated that ticagrelor effectively reduces the risk of major adverse cardiovascular events, including cardiovascular death, myocardial infarction, and stroke. Its rapid onset of action, along with its reversibility, offers advantages in acute settings where immediate platelet inhibition is essential.

Moreover, ticagrelor has been shown to provide a greater reduction in cardiovascular events compared to some traditional antiplatelet agents like clopidogrel, particularly in patients with a higher risk of thrombotic complications.

Side Effects and Safety Profile

While ticagrelor is generally well-tolerated, it is associated with some side effects. Common adverse events include:

• Bleeding : Since ticagrelor is an antiplatelet medication, the risk of bleeding, including minor and major bleeding events, is increased. Patients should be informed of the signs of serious bleeding and monitored accordingly.
• Dyspnea : Some patients may experience shortness of breath, which is generally mild and transient. This effect is thought to be related to ticagrelor’s pharmacological action and is usually manageable.

Other potential side effects may include gastrointestinal disturbances, headache, and elevated uric acid levels, which could lead to gout in predisposed individuals.

Contraindications and Precautions

Ticagrelor should be used with caution in patients with a history of bleeding disorders, active bleeding, or those at high risk for bleeding complications. It is contraindicated in individuals with severe hepatic impairment and those who have a history of hypersensitivity to the drug.

Healthcare providers should also be vigilant when prescribing ticagrelor to patients taking other medications that might interact, such as strong CYP3A4 inhibitors or inducers, which can affect the drug’s metabolism and efficacy.

Withdrawal and Considerations

Discontinuation of ticagrelor should be carefully considered, particularly in patients with a high risk of cardiovascular events. If the medication needs to be stopped, it is essential to ensure that alternative antiplatelet therapy is established if appropriate.

Conclusion

Ticagrelor is a crucial medication within the landscape of cardiovascular care, offering effective platelet inhibition for patients at risk of serious thrombotic events. Its unique mechanism of action, rapid onset, and proven efficacy in clinical studies highlight its importance in the management of acute coronary syndrome and secondary prevention strategies. As with all medications, careful monitoring and patient education are vital to maximize the benefits while minimizing the risks associated with ticagrelor therapy.

Product Image